Clinical and economic burden of heparin-induced thrombocytopenia in hospitalized patients undergoing percutaneous peripheral arterial interventions

Vascular. 2020 Feb;28(1):81-86. doi: 10.1177/1708538119868615. Epub 2019 Aug 5.
No abstract available

Keywords: Peripheral artery disease; heparin-induced thrombocytopenia; outcomes; percutaneous peripheral arterial intervention; thrombosis.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Anticoagulants / administration & dosage*
  • Anticoagulants / economics
  • Cost-Benefit Analysis
  • Databases, Factual
  • Drug Costs
  • Endovascular Procedures / adverse effects
  • Endovascular Procedures / economics*
  • Female
  • Heparin / adverse effects*
  • Heparin / economics
  • Hospital Costs*
  • Hospitalization / economics*
  • Humans
  • Incidence
  • Inpatients
  • Male
  • Middle Aged
  • Peripheral Arterial Disease / economics*
  • Peripheral Arterial Disease / epidemiology
  • Peripheral Arterial Disease / therapy*
  • Risk Factors
  • Thrombocytopenia / chemically induced
  • Thrombocytopenia / economics*
  • Thrombocytopenia / epidemiology
  • Thrombocytopenia / therapy*
  • Time Factors
  • Treatment Outcome
  • United States / epidemiology

Substances

  • Anticoagulants
  • Heparin